Edition:
United Kingdom

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

6.70USD
23 May 2018
Change (% chg)

$0.01 (+0.15%)
Prev Close
$6.69
Open
$6.65
Day's High
$6.97
Day's Low
$6.65
Volume
248,974
Avg. Vol
359,680
52-wk High
$11.26
52-wk Low
$4.32

Select another date:

Tue, May 22 2018

BRIEF-Starboard Value Cuts Stake In Depomed Inc To 4.3 Pct

* STARBOARD VALUE LP CUTS STAKE IN DEPOMED INC TO 4.3 PERCENT AS OF MAY 18 FROM PREVIOUS STAKE OF 6.1 PERCENT AS OF MAY 10 - SEC FILING Source text: (https://bit.ly/2J3k2sc) Further company coverage:

BRIEF-Depomed Q1 Earnings Per Share $0.48

* Q1 EARNINGS PER SHARE VIEW $0.17 -- THOMSON REUTERS I/B/E/S

BRIEF-Depomed Appoints Stan Bukofzer As Chief Medical And Scientific Officer

* DEPOMED ANNOUNCES THE APPOINTMENT OF STAN BUKOFZER, M.D. AS SENIOR VICE PRESIDENT AND CHIEF MEDICAL AND SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

BRIEF-Depomed Inc Files For Mixed Shelf Of Up To $300 Million‍​

* DEPOMED INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2oD3GLe) Further company coverage:

BRIEF-Depomed Reports Q4 GAAP Loss Per Share $0.52

* ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

Select another date: